Mathias Schmidt

Background

About Mathias Schmidt

President and CEO of ArmaGen, Inc. in San Diego, California, President and CEO of JCR USA, Torrance, CA and Senior Executive Director Global Strategy at JCR Pharmaceuticals, Japan, member of the Board of Directors of JCR Pharmaceuticals, Japan. Main responsibilities are to ensure successful global development of JCR assets in lysosomal storage diseases and implement a strategy for global marketing of JCR assets and global outreach of JCR Pharmaceuticals. Over 20 years experience in Pharmaceutical and Biotech industry, including positions in R&D discovery and development, various strategic positions up to C-level experience and fundraising for Biotech. Successfully closed the merger between ArmaGen, Inc. and JCR Pharmaceuticals. Profound discovery and development expertise on chemical and biological entities as exemplified by numerous numerous discovery, preclinical and clinical assets in Orphan diseases, oncology, metabolic diseases and inflammatory diseases. Profound regulatory experience in Orphan Drug Development. Extensive indication background, particularly in rare genetic diseases (lysosomal storage diseases), oncology and immunology. 6 years experience at cancer hospitals in Germany and USA (MD Anderson Cancer Center, Houston) Venia legendi in pharmacology and cell biology & lecturer at University of Constance;~50 publications in peer-reviewed journals; author or co-author of multiple PCT applications. Strong track record of internalizing innovation, including establishment, implementation & heading of target scouting process & early alliancing; established robust network to Universities and Biotech arena. Key attributes: open-minded and approachable, excellent communicator, start-to-finish mentality, strong motivator, relationship builder, entrepreneurial thinker. Specialties: Strategic leadership, Orphan drug development, Biotech, fundraising, Oncology, drug discovery and development, biopharmaceuticals, blood-brain barrier, strategic planning, Pharma-Biotech partnerships, early alliancing, target scouting